Sirolimus-induced acneiform eruption

Dermatology

Volumn 211, Issue 4, 2005, Pages 366-369

  Kunzle, N ^a   Venetz, J P ^a   Pascual, M ^a   Panizzon, R G ^a   Laffitte, E ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Acne; Drug eruption; Sirolimus; Transplantation

Indexed keywords

ADAPALENE; BENZOYL PEROXIDE; DOXYCYCLINE; ERYTHROMYCIN; RAPAMYCIN;

ACNE; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; FEMALE; HUMAN; KIDNEY ALLOGRAFT; KIDNEY FAILURE; MICROCYTIC ANEMIA; PAPULE; PRIORITY JOURNAL; PUSTULE; RECIPIENT; RENAL GRAFT DYSFUNCTION;

ACNEIFORM ERUPTIONS; ADULT; DRUG ERUPTIONS; FACIAL DERMATOSES; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 27844586914     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088511     Document Type: Article

References (17)

1. Vasquez EM: Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health Syst Pharm 2000;57:437-448; quiz 449-451.
2. Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, et al: Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004;15:809-817.
3. Magee CC, Pascual M: Update in renal transplantation. Arch Intern Med 2004;164:1373-1388.
4. Bedane C, Souyri N: Induced acne (in French). Ann Dermatol Venereol 1990;117:53-58.
5. O'Connell BM, Abel EA, Nickoloff BJ, Bell BJ, Hunt SA, Theodore J, et al: Dermatologic complications following heart transplantation. J Heart Transplant 1986;5:430-436.
6. el-Shahawy MA, Gadallah MF, Massry SG: Acne: a potential side effect of cyclosporine A therapy. Nephron 1996;72:679-682.
7. Pham PT, Pham PC, Danovitch GM, Ross DJ, Gritsch HA, Kendrick EA, et al: Sirolimus-associated pulmonary toxicity. Transplantation 2004;77:1215-1220.
8. Mahé E, Morelon E, Ducasse M, Kreis H, De Prost Y, Bodemer C: Evaluation dermatologique de 71 patients transplantés rénaux sous immunosuppression comprenant du sirolimus. Ann Dermatol Venereol 2003;130:4S65.
9. Montalbano M, Neff GW, Yamashiki N, Meyer D, Bettiol M, Slapak-Green G, et al: A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 2004;78:264-268.
10. Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE: Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001;145:438-445.
11. Kahan BD: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000;356:194-202.
12. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-2347.
13. Dereure O: Skin reactions related to treatment with anticytokines, membrane receptor inhibitors and monoclonal antibodies. Expert Opin Drug Saf 2003;2:467-473.
14. Laffitte E, Saurat JH: Kinase inhibitor-induced pustules. Dermatology 2005;211:305-306.
15. Mimeault M, Bonenfant D, Batra SK: New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation, disorders and cancers. Skin Pharmacol Physiol 2004;17:153-166.
16. Nomura M, He Z, Koyama I, Ma WY, Miyamoto K, Dong Z: Involvement of the Akt/mTOR pathway on EGF-induced cell transformation. Mol Carcinog 2003;38:25-32.
17. Marcusson JA, Tyden G: Acne conglobata in transplant patients treated with isotretinoin. Br J Dermatol 1988;118:310-312.